Ambrx Biopharma's oncology segment is dedicated to the discovery and development of innovative cancer therapies, primarily focused on antibody-drug conjugates (ADCs). This segment leverages Ambrx's proprietary expanded genetic code technology to engineer precision biologics that target specific cancer markers. Key research and development activities include preclinical studies, Phase 1, 2, and 3 clinical trials for product candidates like ARX788 (anti-HER2 ADC) for breast and gastric cancers, ARX517 (anti-PSMA ADC) for prostate cancer, and ARX305 (anti-CD70 ADC) for renal cell carcinoma. The goal is to improve patient outcomes by delivering targeted therapies that minimize off-target effects and maximize efficacy. This segment aims to establish a strong market position by addressing unmet needs in cancer treatment and developing novel therapeutic approaches.

This segment focuses on the research, development, and application of Ambrx's proprietary expanded genetic code technology platform. This platform enables the creation of novel, engineered precision biologics with enhanced properties and functionalities. Research and development efforts are directed towards optimizing the platform for various applications, including the design of antibody-drug conjugates (ADCs), immunomodulatory proteins, and other therapeutic modalities. The technology allows for the precise incorporation of non-natural amino acids into proteins, enabling the creation of biologics with improved targeting, efficacy, and safety profiles. This segment supports the development of Ambrx's internal product pipeline and facilitates collaborations with pharmaceutical partners seeking to leverage the platform for their own drug development programs. The platform's unique capabilities provide a competitive advantage in the development of next-generation biologics.